BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23590708)

  • 1. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas.
    Bao Z; Zhang C; Yan W; Liu Y; Li M; Zhang W; Jiang T
    J Transl Med; 2013 Apr; 11():100. PubMed ID: 23590708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas.
    Wang H; Zhao Y; Zhang C; Li M; Jiang C; Li Y
    PLoS One; 2014; 9(2):e89782. PubMed ID: 24587032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.
    Bao ZS; Li MY; Wang JY; Zhang CB; Wang HJ; Yan W; Liu YW; Zhang W; Chen L; Jiang T
    CNS Neurosci Ther; 2014 Feb; 20(2):112-8. PubMed ID: 24279471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP4, a new prognostic factor for glioma.
    Wu Q; Yao J
    World J Surg Oncol; 2013 Oct; 11():264. PubMed ID: 24099560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAB34 was a progression- and prognosis-associated biomarker in gliomas.
    Wang HJ; Gao Y; Chen L; Li YL; Jiang CL
    Tumour Biol; 2015 Mar; 36(3):1573-8. PubMed ID: 25501506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling.
    Lu FF; Wang HY; He XZ; Liang TY; Wang W; Hu HM; Wu F; Liu YW; Zhang SZ
    J Neurooncol; 2017 Sep; 134(2):397-405. PubMed ID: 28752501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas.
    Liu C; Tian G; Tu Y; Fu J; Lan C; Wu N
    Jpn J Clin Oncol; 2009 Oct; 39(10):625-31. PubMed ID: 19797419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
    J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
    Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
    PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
    Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
    J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway.
    Jin X; Nie E; Zhou X; Zeng A; Yu T; Zhi T; Jiang K; Wang Y; Zhang J; You Y
    Cell Physiol Biochem; 2017; 44(4):1616-1628. PubMed ID: 29212066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation of bone morphogenetic protein 2 with poor prognosis in glioma patients.
    Yang X; Li D; Cheng S; Fan K; Sheng L; Zhang J; Feng B; Xu Z
    Tumour Biol; 2014 Nov; 35(11):11091-5. PubMed ID: 25099618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis.
    Reon BJ; Anaya J; Zhang Y; Mandell J; Purow B; Abounader R; Dutta A
    PLoS Med; 2016 Dec; 13(12):e1002192. PubMed ID: 27923049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental validation of 5 in-silico predicted glioma biomarkers.
    Towner RA; Jensen RL; Vaillant B; Colman H; Saunders D; Giles CB; Wren JD
    Neuro Oncol; 2013 Dec; 15(12):1625-34. PubMed ID: 24158112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
    Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
    J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.